BridgeBio Pharma Inc (NASDAQ:BBIO) price on Thursday, February 06, fall -2.50% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $32.70.
A look at the stock’s price movement, the close in the last trading session was $33.54, moving within a range at $32.59 and $33.94. The beta value (5-Year monthly) was 1.086. Turning to its 52-week performance, $41.04 and $21.62 were the 52-week high and 52-week low respectively. Overall, BBIO moved 15.71% over the past month.
BridgeBio Pharma Inc’s market cap currently stands at around $6.18 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 4.04M for the company’s revenue for the quarter, with a low and high estimate of 500k and 16.5M respectively. The average forecast suggests up to a 131.48% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 281.76M, representing a 2,928.71% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that BBIO is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
9 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 9 recommend BBIO as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
BBIO’s current price about -4.84% and 8.11% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 49.60, while 7-day volatility ratio is 6.55% and 5.78% in the 30-day chart. Further, BridgeBio Pharma Inc (BBIO) has a beta value of 1.07, and an average true range (ATR) of 1.73. Analysts have given the company’s stock an average 52-week price target of $46, forecast between a low of $45 and high of $53. Looking at the price targets, the low is -37.61% off current price level while to achieve the yearly target high, price needs to move -62.08%. Nonetheless, investors will most likely welcome a -40.67% jump to $46 which is the analysts’ median price.
If we refocus on BridgeBio Pharma Inc (NASDAQ:BBIO), historical trading data shows that trading volumes averaged 2.65 over the past 10 days and 2.53 million over the past 3 months. The company’s latest data on shares outstanding shows there are 188.99 million shares.
The 21.49% of BridgeBio Pharma Inc’s shares are in the hands of company insiders while institutional holders own 74.15% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 20.38 million on 2025-01-15, giving us a short ratio of 8.07. The data shows that as of 2025-01-15 short interest in BridgeBio Pharma Inc (BBIO) stood at 1655.9999999999998 of shares outstanding, with shares short rising to 17.12 million registered in 2024-12-13. Current price change has pushed the stock 19.17% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the BBIO stock continues to rise going into the next quarter.
